Physician profile
Robert N Corriel
NPI 1588669519
$23,556.28
in general payments reported to CMS, 2019-2025
46 companies · $5,535 in 2025
The $5,535 reported for 2025 was more than what 84% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.20 · 2020: $1,185 · 2021: $2,515 · 2022: $4,276 · 2023: $4,995 · 2024: $4,964 · 2025: $5,535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $88.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,404.79 |
| Education | $88.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,514.28 | 2020-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $3,095.21 | 2020-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $2,695.88 | 2020-2025 | Airsupra, Tezspire, Breztri |
| Genzyme Corporation | $2,533.23 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,085.55 | 2020-2025 | Cuvitru, Takhzyro, Glassia |
| Pfizer INC. | $1,021.50 | 2020-2025 | |
| Incyte Corporation | $953.76 | 2021-2025 | Opzelura, Opzelura |
| Grifols USA, LLC | $931.74 | 2020-2025 | Xembify |
| Amgen INC. | $885.52 | 2021-2025 | Tezspire, Actimmune |
| Kaleo, INC. | $771.53 | 2020-2024 | Auvi-Q |
| Optinose US, INC. | $651.36 | 2021-2024 | |
| Genentech USA, INC. | $568.04 | 2019-2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $560.82 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $422.26 | 2023-2025 | Orladeyo |
| Blueprint Medicines Corporation | $412.82 | 2021-2025 | Ayvakit |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Corriel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.